Türkmen, KültiginErdur, Fatih MehmetDalmaz, MahmutYeksan, MehdiAkkuş, İdrisTürk, Süleyman2020-03-262020-03-2620131300-7718https://dx.doi.org/10.5262/tndt.2013.1001.13https://hdl.handle.net/20.500.12395/30225OBJECTIVE: Recombinant human erythropoietin (r-HuEPO) was found to be associated with increased blood pressure in hemodialysis (HD) patients. Plasma endothelin-1(ET-1) was reported to be increased during treatment with r-huEPO in HD patients. Prostacyclin (PGI2) was found to be associated with the reduction in vascular resistance. We aimed to determine the role of ET-1 and PGI2 on r-huEPO-induced hypertension in HD patients. MATERIAL and Methods: 43 HD patients (19 females, 24 males) were randomly assigned to groups. Group 1 (n=15) consisted of patients receiving r-HuEPO-? subcutaneously after each dialysis session for 6 to 42 months. Group 2 (n=15, control group) consisted of patients who did not receive any r-huEPO and group 3 (n=13) consisted of patients who received r-huEPO-? subcutaneously after each dialysis session for 12 weeks. Plasma ET-1,2 and 6-keto-PGF1-? were measured. Results : There were no differences in terms of ET-1,2 and 6-keto-PGF1-?, systolic and diastolic BP and hematocrit levels in group 1 and group 2 patients. However, in group 3 patients, hematocrit, plasma ET1,2 and 6-keto PGF1-? levels were significantly elevated after 12 weeks of rHuEPO treatment. Conclusion: We showed that ET-1.2 and 6-keto-PGF1-? levels were found to be significantly increased with 12 weeks of rHu-EPO therapy in HD patients.en10.5262/tndt.2013.1001.13info:eu-repo/semantics/closedAccessEndothelinErythropoietinHemodialysisHypertensionProstacyclinArticle2218994N/A